TrialThe Journal of clinical endocrinology and metabolism2014

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.

Ciara O'Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.